DiaSorin (DIA) investor relations material

Strategic vision and market positioning

• U.S. market now represents about 50% of revenues, driven by Luminex acquisition and expansion in molecular diagnostics, with a focus on high-value segments like autoimmunity, GI, and hypertension.

• Five-year plan leverages specialty leadership in immunodiagnostics, molecular diagnostics, and life sciences, emphasizing innovation, automation, and precision medicine.

• Addresses macro healthcare trends: demographic shifts, lab consolidation, decentralization, value-based care, and precision medicine.

• Committed to launching over 20 new specialty immunodiagnostic assays and new molecular platforms by 2030, expanding reach among academic and biopharma customers.

• Growth strategy includes expanding hospital penetration, especially in the U.S., and strengthening partnerships in the pharmaceutical sector.

Financial guidance and capital allocation

• Revenue CAGR guidance is 6–8% through 2030, with 2026 growth at 5–6%, and adjusted EBITDA margin targeted to rise from 32–33% in 2026 to 34–35% by 2030.

• Immunodiagnostics expected to grow mid-single digits, molecular diagnostics at high teens post-2026, and licensed technologies to contribute 10% of revenues by 2030.

• Cumulative free cash flow of approximately €1 billion projected for 2027–2030, with capital allocation prioritizing organic growth, progressive dividends, targeted M&A, and selective buybacks.

• Margin expansion to be achieved through disciplined cost management, industrial efficiencies, and digital/AI-driven process optimization.

• Financials are presented at constant exchange rates for comparability.

Business developments and innovation

• LIAISON NES and PLEX platforms are central to molecular growth, with NES targeting $150M in U.S. sales and PLEX €180M globally by 2030.

• NES offers rapid, multiplexed, CLIA-waived testing for respiratory and, in the future, women's health and STI, with strong distributor partnerships.

• PLEX enables customizable panels, supporting diagnostic stewardship and cost-effective care, with strong adoption in U.S. hospitals.

• Immunodiagnostics pipeline includes Calprotectin HD for IBD/IBS, MeMed for antibiotic stewardship, and expansion into autoimmunity and complementary diagnostics.

• Licensed technologies drive recurring revenue through diagnostics, life science research, pharma partners, and scalable monetization via kits, consumables, instruments, and royalties.